HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
|Articles|May 11, 2010
Conditions Recommended for Addition
Should the Task Force add more conditions to DSM5? If so, what are they? Some of the recommendations for addition include:
Advertisement
Should the Task Force add more conditions to DSM5? If so, what are they? Some of the recommendations for addition include:
• Apathy Syndrome
• Body Integrity Identity Disorder
• Complicated Grief Disorder
• Developmental Trauma Disorder
• Disorders of Extreme Stress
• Fetal Alcohol Syndrome
• Internet Addiction
• Male-to-Eunuch Gender Identity Disorder
• Melancholia
• Parental Alienation Disorder
• Seasonal Affective Disorder
• Sensory Processing Disorder
Related Content
Advertisement
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges
5